//
Satoshi Nishiwaki
Koichi Miyamura
Kazuteru Ohashi
Junji Tanaka
Mineo Kurokawa
Shuichi Taniguchi
Takahiro Fukuda
Kazuhiro Ikegame
Hisashi Sakamaki
Yasuo Morishima
Koji Kato
Ritsuro Suzuki
Department of Pathologic Oncology, Mie University Graduate School of Medicine, Mie, Japan
Department of HSCT Data Management/Biostatistics, Nagoya University Graduate School of Medicine, Nagoya, Japan
Department of Pediatrics, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
Department of Hematology, Toranomon Hospital, Tokyo, Japan
Department of Cell Therapy and Transplantation Medicine, The University of Tokyo Hospital, Tokyo, Japan
Department of Radiology, Okayama University Graduate School of Medicine, Okayama, Japan
Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan
Department of Stem Cell Transplantation, National Cancer Center, Tokyo, Japan
Department of Pediatrics, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
Japan
N/A
Oncology (ONC)
Acute lymphoblastic leukemia
Breakpoint Cluster Region
Allopurinol
N/A
N/A
NA
N/A
N/A
N/A